Please select the option that best describes you:

Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?   



Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at Lake Huron Medical Center
What a great answer. Thanks for that
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
Your wise words are spot on once again. My advice ...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Radiation Oncology Associates
I respectfully disagree. Ablate: "To take away, re...
Radiation Oncologist at Turville Bay MRI & Radiation Oncology Center
Based on this, you would presumably favor 74 Gy th...
Radiation Oncologist at San Francisco CyberKnife
Nothing Dr. Kittel wrote made any reference to RTO...
Sign in or Register to read more